Blinatumomab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Blinatumomab and local guidelines before prescribing.
Bispecific T-cell engager
Mechanism
CD19/CD3 bispecific T-cell engager.
Uses
Relapsed or refractory B-cell acute lymphoblastic leukaemia.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Cytokine release syndrome, neurotoxicity, infections, neutropenia.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active infection
Monitoring
FBC, neurology
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive; tocilizumab for CRS
Special advice
Continuous infusion with dexamethasone premedication; monitor neurology.
More from the textbook: uses, cautions and other points
- Blinatumomab and other bispecific antibodies; CAR-T cells | ALL, lymphoma, myeloma | Cytokine release syndrome (fever, low BP - tocilizumab), neurotoxicity (ICANS), infections, low antibodies
Haematology: Anatomy Physiology and Pharmacology - Blinatumomab / inotuzumab | ALL immunotherapy; CRS and neurotoxicity (blinatumomab); liver VOD (inotuzumab).
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Bispecific T-cell engagers (blinatumomab, teclistamab, glofitamab, epcoritamab) cause similar toxicities.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology - Immunotherapy - blinatumomab , inotuzumab ozogamicin , CAR-T cells for relapsed or residual disease.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia